Document is current
Any future updates will be listed below
-
Authors
Gómez-Aleza, Clara https://orcid.org/0000-0002-4645-5719
Nguyen, Bastien https://orcid.org/0000-0002-6166-4746
Yoldi, Guillermo
Ciscar, Marina
Barranco, Alexandra
Hernández-Jiménez, Enrique https://orcid.org/0000-0002-8232-8151
Maetens, Marion
Salgado, Roberto
Zafeiroglou, Maria
Pellegrini, Pasquale
Venet, David
Garaud, Soizic
Trinidad, Eva M. https://orcid.org/0000-0001-6090-5205
Benítez, Sandra https://orcid.org/0000-0001-9645-7088
Vuylsteke, Peter
Polastro, Laura
Wildiers, Hans https://orcid.org/0000-0001-8990-7837
Simon, Philippe
Lindeman, Geoffrey https://orcid.org/0000-0001-9386-2416
Larsimont, Denis
Van den Eynden, Gert
Velghe, Chloé
Rothé, Françoise
Willard-Gallo, Karen https://orcid.org/0000-0002-1150-1295
Michiels, Stefan https://orcid.org/0000-0002-6963-2968
Muñoz, Purificación
Walzer, Thierry
Planelles, Lourdes
Penninger, Josef
Azim, Hatem A. Jr
Loi, Sherene https://orcid.org/0000-0001-6137-9171
Piccart, Martine
Sotiriou, Christos https://orcid.org/0000-0002-5745-9977
González-Suárez, Eva https://orcid.org/0000-0003-0858-8171
- License Information
-
More Information
Article History
Received: 9 June 2020
Accepted: 12 November 2020
First Online: 10 December 2020
Competing interests
: R.S. reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from BMS for an advisory board meeting and from Roche for an advisory board related to a trial-research project. H.A.A. is advisory board at Roche and current employee of Innate Pharma. E.G.S. and G.J.L. have served on advisory boards for Amgen and has received honoraria and research funding from Amgen. S.L. receives research funding from Novartis, Merck, BMS, Roche-Genentech, Puma Biotechnology, Pfizer, and uncompensated advisory board of Novartis, Merck, BMS, Roche-Genentech, Puma Biotechnology, Pfizer, and Seattle Genetics. The remaining authors declare no competing interests.
